Acute Pelvic Inflammatory Disease

© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )

Download PDF

Cite

XML

Abstract

Pregnant women of reproductive age continue to be a major public health concern. It is linked to serious long-term consequences such as tubal factor infertility, pregnancy, and persistent pelvic discomfort. Furthermore, the treatment of acute PID and its consequences incurs significant healthcare expenses. Preventing these long-term consequences requires doctors to have a high index of suspicion in order to make an early diagnosis and devise treatment methods based on the understanding of the microbiologic etiology of acute PID. A polymicrobial infection is widely regarded as the cause of acute PID. In many cases, sexually transmitted organisms such as Neisseria gonorrhoeae and Chlamydia trachomatis are present, while microbes from the endogenous vaginal and cervical flora are usually associated with PID. This comprises anaerobic and facultative bacteria, which are related to bacterial vaginosis. Mycoplasmas of the vaginal tract, most notably Mycoplasma genitalium, have lately been linked to acute PID. As a result, treatment regimens for acute PID should include wide spectrum coverage that is effective against these pathogens.

Keywords

Pelvic inflammatory disease (PID)

Genital tract inflammation

Sexually Transmitted Disease (STD).

Conflict of interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Menezes MLB, Giraldo PC, Linhares IM, Boldrini NAT, Aragon MG. Brazilian protocol for sexually transmitted infections, 2020: Pelvic inflammatory disease. Rev Soc Bras Med Trop 2021;54(suppl 1):e2020602.
2. Kerry-Barnard S, Zhou L, Phillips L, Furegato M, Witney AA, Sadiq ST, et al. Vaginal microbiota in ethnically diverse young women who did or did not develop pelvic inflammatory disease: Community-based prospective study. Sex Transm Infect 2022;98(7):503–9.
3. Li M, McDermott R. Smoking, poor nutrition, and sexually transmitted infections associated with pelvic inflammatory disease in remote North Queensland Indigenous communities, 1998-2005. BMC Womens Health 2015;15:31.
4. Greydanus D, Bacopoulou F. Acute pelvic inflammatory disease: A narrative review. Pediatr Med 2019;2:36.
5. Iwata H, Sugiyama Y, Satoi Y, Sasamoto N, Aoki T, Matsushima M. Diagnostic accuracy of pelvic examination in pelvic inflammatory disease: A meta-analysis. J Gen Fam Med 2022;23:1–9.
6. Zhou Z, Zeng F, Yuan J, Tang J, Colditz GA, Tworoger SS, et al. Pelvic inflammatory disease and the risk of ovarian cancer: A meta-analysis. Cancer Causes Control 2017;28(5):415–28.
7. Kreisel K, Torrone E, Bernstein K, Hong J, Gorwitz R. Prevalence of pelvic inflammatory disease in sexually experienced women of reproductive age - United States, 2013-2014. MMWR Morb Mortal Wkly Rep 2017;66:80–3.
8. Mitchell CM, Anyalechi GE, Cohen CR, Haggerty CL, Manhart LE, Hillier SL. Etiology and diagnosis of pelvic inflammatory disease: Looking beyond gonorrhea and chlamydia. J Infect Dis 2021;224(12 suppl 2):S29–35.
9. Savaris RF, Fuhrich DG, Duarte RV, Franik S, Ross JDC. Antibiotic therapy for pelvic inflammatory disease: An abridged version of a cochrane systematic review and meta-analysis of randomised controlled trials. Sex Transm Infect 2019;95:21–7.
10. Xu SX, Gray-Owen SD. Gonococcal pelvic inflammatory disease: Placing mechanistic insights into the context of clinical and epidemiological observations. J Infect Dis 2021;224(12 Suppl 2):S56–63.
11. Sweeney S, Bateson D, Fleming K, Huston W. Factors associated with pelvic inflammatory disease: A case series analysis of family planning clinic data. Womens Health Lond 2022;18:17455057221112263.
12. Eschenbach, D. A. Acute pelvic inflammatory disease. The urologic clinics of North America 1984;11:65-81.
13. Sweet RL. Treatment of acute pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011;2011:1–13.
14. Scheidell JD, Thorpe LE, Adimora AA, Caniglia EC, Lejuez CW,
Troxel AB, et al. Perceived stress, sexually transmitted infection, and pelvic inflammatory disease: Examination of differences in associations among black and white women. Sex Transm Dis 2020;47:617–24.
15. Savaris RF, Fuhrich DG, Maissiat J, Duarte RV, Ross J. Antibiotic therapy for pelvic inflammatory disease. Cochrane Database Syst Rev 2020;8:CD010285.
16. Tang B, Wu K, Meng Q, Wang F. Comparison of the analgesic and anti-inflammatory effects of xiaoyuningkun decoction with cynanchum paniculatum and fukeqianjin in a mouse model of pelvic inflammatory disease. Med Sci Monit 2019;25:9094–102.
17. Turpin R, Tuddenham S, He X, Klebanoff MA, Ghanem KG,
Brotman RM. Bacterial vaginosis and behavioral factors associated with incident pelvic inflammatory disease in the longitudinal study of vaginal flora. J Infect Dis 2021;224(12 Suppl 2):S137–44.
18. Borase RP, Maghade DK, Sondkar SY, Pawar SN. A review of PID control, tuning methods and applications. Int J Dyn Control 2021;9:818–27.
19. Somefun OA, Akingbade K, Dahunsi F. The dilemma of PID tuning. Annu Rev Control 2021;52:65–74.
20. Berner J, Soltesz K, Hägglund T, Åström KJ. An experimental comparison of PID autotuners. Control Eng Pract 2018;73:124– 33.
21. Nordin J, Solís L, Prévot J, Mahlaoui N, Chapel H, SánchezRamón S, et al. The PID principles of care: Where are we now? A global status report based on the PID life index. Front Immunol 2021;12:780140

Previous article in this issue

Next article in this issue

Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing